A guide to the archive · Medicine
The treatment. The evidence. The consequences.
Medical harm can begin in a hospital routine, a medicine’s formulation or a decision about which evidence is enough. These histories follow those decisions and the people affected by them, then examine how practice and oversight changed.
Start with three different questions: how did a ward become safer, why did a familiar drug become a poisonous mixture, and what happened when a reviewer asked for stronger evidence? Each article links the records and research behind its account.
These cases concern different points in care: contact with a patient, preparation of a medicine, and permission to distribute it. Comparing those points explains why a successful safeguard in one place can leave another route to harm open. This is a comparison of historical decisions, not treatment guidance.
Scroll across the table to compare all four columns.
| Case | Mechanism and decision | Evidence to follow | Limit of the conclusion |
|---|---|---|---|
| Semmelweis, 1847 | Change the ward routine: disinfect hands between patients to interrupt contamination carried by attendants. | CDC’s historical review compares the two clinics and reports the fall in mortality after chlorine hand cleansing. | The ward comparison supports the intervention. It does not identify the transmission route for every individual death or show that everyone immediately adopted the practice. |
| Elixir Sulfanilamide, 1937 | Examine the complete formulation before sale: the poisonous solvent created a danger absent from experience with tablets and powders. | FDA documents the omitted toxicity tests and the investigation identifying diethylene glycol. Its legal history explains the later requirement to establish new-drug safety before marketing. | An established active ingredient does not establish the safety of a new mixture. The disaster accelerated reform that was already being debated. |
| Thalidomide, 1960–1962 | Require adequate evidence for a market application, while also controlling the investigational route through which patients receive a drug. | FDA’s history records both Kelsey’s refusal to let the unsupported Kevadon application become effective and Merrell’s distribution of over two million investigational tablets. | Blocking general marketing did not mean zero U.S. exposure. Tablets distributed are not a count of patients, injuries, or births prevented. |
1847–1861 · 2 min read
How did a hospital routine spread harm?
In 1847, Semmelweis introduced chlorine-based hand disinfection in a Vienna maternity clinic, and deaths from childbed fever fell sharply. Follow the comparison between wards and the reception of his findings. He faced resistance, but also had supporters; the familiar lone-genius version leaves out that complexity.
Read the supporting sources →1937 · 3 min read
Why did a familiar drug become a deadly mixture?
The liquid sulfanilamide preparation sold in 1937 used poisonous diethylene glycol as its solvent and had not undergone toxicity testing. More than 100 people died. The article follows the evidence, the search for distributed bottles and the gap in federal law that the disaster exposed.
Read the supporting sources →1957–1962 · 2 min read
What difference could one review make?
Frances Kelsey repeatedly sought stronger evidence for the original U.S. thalidomide application despite company pressure. Researchers then linked the drug to severe birth defects. Read why withholding that market approval mattered, and why it does not mean that nobody in the United States was exposed.
Read the supporting sources →